Inside Precision Medicine May 7, 2024
Broken String Biosciences and the Francis Crick Institute are partnering to develop novel applications for the start-up’s proprietary DNA break-mapping platform, INDUCE-seq, to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS). The partnership will examine DNA break-mapping technology and advance understanding of genomic instability in the development of ALS.
Felix Dobbs, PhD, CEO, Broken String Biosciences, said, “This collaboration with the Crick Institute is validation of our differentiated approach to DNA break-mapping; enabling our team to support world-leading research with insights provided through our INDUCE-seq platform. It demonstrates a fantastic opportunity to apply our expertise across other key research areas to support the advancement of human health.”
The collaboration combines the interests of Simon...
Today's Sponsors
Today's Sponsor